Theravance Biopharma, Inc. 4

Insider Aine Miller had 6,258 Theravance Biopharma ordinary shares withheld by the issuer at $16.95 per share to cover taxes on RSU vesting, leaving her with 189,826 shares owned directly.

On August 20, 2026, Aine Miller, SVP, Development & Head of Ireland Office at Theravance Biopharma, Inc., had 6,258 ordinary shares withheld by the issuer at an implied price of $16.95 per share to cover tax obligations arising from the vesting of previously granted restricted stock units, a non-open-market, administrative transaction. Following this tax withholding, Miller’s direct ownership stood at 189,826 ordinary shares, which, using the same $16.95 reference price, represents an estimated post-transaction holding value of approximately $3.22 million.

Filing Facts

CIK

1583107

Ticker

TBPH

Form

4

Source Type

fda

Accession

0002012524-26-000008

Alert Tier

5